Nontuberculous Mycobacteria in Guadeloupe, Martinique, and French Guiana from 1994 to 2012

Table 2

Isolation patterns of regularly encountered NTM.

Parameters	Total	M. gordonae	M. kansasii	M. marinum	M. simiae	M. terrae complex	M. xenopi
Years
1994–1998	158	9	9	2	11	2	3
1999–2003	166	14	11	2	5	22	2
2004–2008	182	8	10	1	10	1	2
2009–2012	145	10	3	1	9	0	1
	651	41	33	6	35	25	8
Age
≤19	18	1	0	1	0	2	0
20–39	122	4	8	1	2	5	0
40–54	166	8	12	1	7	6	4
55–69	125	14	4	1	6	5	1
≥70	130	12	6	1	6	5	1
NA	90	2	3	1	14	2	2
Sex ratio	1.63	1.22	1.21	2	1.2	3.6	—
(M/F)	(380/233)	(22/18)	(17/14)	(4/2)	(18/15)	(18/5)	(8/0)
NA	—	1	2	—	2	2	—
HIV (pos/neg)^a	129/96	3/11	5/2	NA	9/3	2/2	0/1
Department
GLP	270	15	29	0	25	0	3
MTQ	194	21	4	5	6	3	5
GUF	187	5	0	1	4	22	0
Drug-susceptibility pattern^b; (nb tested)	—	OFLO 5, EMB, D-CS, CIPRO 1.5, SPARFLO, CLARIT; (𝑛, 38)	ETH, RIF 1, EMB, CLOFA, RBT, CLARIT; (𝑛, 30)	ETH, RIF 15, EMB, DCS; (𝑛, 6)	CLOFA, CLARIT; (𝑛, 32)	ETH, RIF 15, EMB, CLOFA, RBT, CLARIT; (𝑛, 25)	ETH, INH 1, OFLO, EMB, D-CS, KANA, AMIK 4, CLOFA, RBT, CIPRO 1.5, SPARFLO, CLARIT; (𝑛, 6)

aFor patients with known HIV serology.
NA: not available; GLP: Guadeloupe; MTQ: Martinique; GUF: French Guiana.
bDrug-susceptibility pattern for a given NTM species was defined as ≤10% of all isolates displaying in vitro resistance [10]; AMIK: amikacin; CIPRO: ciprofloxacin; CLARIT: clarithromycin; CLOFA: clofazimine; D-CS: D-cycloserine; OFLO: ofloxacin; RBT: rifabutin; RIF: rifampin; SPARFLO: sparfloxacin. Note that drug concentration is mentioned for drugs screened at 2 different concentrations.